The UK and US have hammered out a significant trade agreement that will keep zero import taxes on UK pharmaceutical shipments entering the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has committed to raise expenditure on medicines through the NHS. This commitment ensures that duties on these crucial exports will stay at zero for a duration of three years.
This agreement is in response to recent threats to significantly raise tariffs on patented drug products, with figures mentioned up to 100%.
"This deal between the United Kingdom bolsters the worldwide climate for cutting-edge drugs and introduces long-overdue balance to transatlantic drug exports," a statement said.
Economic Impact
Medicines are one of the Britain's most significant goods shipped to the United States, which is by far the primary destination for leading British pharmaceutical firms.
Trade data reveal that in the 12 months to the end of last September, the UK sold pharmaceutical products valued at £11.1bn to the US. This figure made up a significant portion of British export trade in that span.
"This deal protects jobs, increases capital expenditure and facilitates the UK to become a worldwide center for life sciences," a government official remarked.
Key British Pledges
The deal entails several key changes from the British government:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new therapies to be unaffordable by 25%.
- Increased NHS Spending: There is a target to increase total public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The sum manufacturers must return to the NHS to stay within budget will be limited at fifteen percent. Previously, rebates topped twenty percent.
Industry Background
This agreement takes place against a long-running dispute between the pharmaceutical industry and the UK government over medicine costs and approval rates.
This friction were exacerbated by assertions that American patients were charged significantly more for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several large manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been announced toward US facilities.
A senior figure publicly accepted that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had declined as a proportion of its total funding over the last ten years.
